Figure 6.

Modulatory effect of linagliptin and liraglutide on glucose (20 mmol/L)- and angiotensin II (10⁻⁷ mol/L)-changes of phospho-ERK1/2 and phospho-NF-κB-p65 in cardiac fibroblasts. Both liraglutide and linagliptinin in all concentrations significantly inhibits glucose-induced expression of phospho-ERK1/2 and phospho-NF-κB-p65 in cardiac fibroblasts. Liraglutide in all concentrations also significantly inhibits angiotensin II-induced expression of phospho-ERK1/2 and phospho-NF-κB-p65. Linagliptin except dose at 0.3 nmol/L also inhibits angiotensin II-induced expression of phospho-ERK1/2 and phospho-NF-κB-p65. Mean±SD. Bar graphs represent data from 4 independent experiments. ^*P<0.01 vs control. ^ΔP<0.05, ^#P<0.01 vs glucose or angiotensin II alone.